Published in TB and Outbreaks Week, January 11th, 2000
ViroPharma will use Battelle's inhalation technology in combination with ViroPharma's small molecule antiviral drug candidates for the treatment of respiratory syncytial virus (RSV) disease. ViroPharma is responsible for the development, manufacturing, and commercialization of all RSV products.
"RSV disease represents a serious health threat to individuals of all ages," said Claude H. Nash, ViroPharma. "There is an urgent need...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.